Valuation: Celcuity Inc.

Market Cap 5B 4.38B 4.04B 3.77B 7.1B 473B 7.27B 48.63B 18.77B 233B 18.78B 18.36B 810B P/E 2026 *
-25.5x
P/E 2027 * -213x
Enterprise Value 5B 4.38B 4.04B 3.77B 7.1B 473B 7.27B 48.63B 18.77B 233B 18.78B 18.36B 810B EV / Sales 2026 *
119x
EV / Sales 2027 * 13.1x
Free-Float
89.97%
Yield 2026 *
-
Yield 2027 * -
1 day+2.57%
1 week+14.00%
Current month-22.85%
1 month-22.85%
3 months-3.30%
6 months+0.96%
Current year+2.79%
1 week 89.64
Extreme 89.64
103.31
1 month 82.55
Extreme 82.5536
134.7
Current year 82.55
Extreme 82.5536
151.02
1 year 12.48
Extreme 12.48
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 2011-12-31
Chief Executive Officer 64 2011-12-31
Director of Finance/CFO 59 2017-06-30
Director TitleAgeSince
Chairman 64 2011-12-31
Director/Board Member 64 2011-12-31
Director/Board Member 67 2014-01-31
Date Insider Type Main position Quantity % Market Cap.
Jun. 09Don

Director

-25,006 0.0540%
Jun. 09Don

Director

-28,096 0.0607%
Jun. 04Free

Director

1,530 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%+14.00%+717.54%+836.26% 5B
+2.14%-1.33%+70.75%+125.72% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+6.84%+7.99%+40.30%-28.49% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +4.12%+8.06%+133.43%+224.42% 23.16B
Weighted average by Cap. +4.21%+7.84%+80.50%+157.57%

Financials

2026 *2027 *
Net sales 42.08M 36.84M 34.01M 31.76M 59.79M 3.98B 61.15M 409M 158M 1.96B 158M 155M 6.81B 383M 335M 310M 289M 544M 36.21B 557M 3.73B 1.44B 17.86B 1.44B 1.41B 62.01B
Net income -218M -191M -176M -164M -309M -20.58B -316M -2.12B -818M -10.15B -818M -800M -35.26B -34.95M -30.6M -28.25M -26.38M -49.66M -3.3B -50.79M -340M -131M -1.63B -131M -128M -5.66B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
26-06-29 $102.52 +2.57% 1,032,384
26-06-26 $99.95 +4.19% 2,565,086
26-06-25 $95.93 -0.47% 1,446,315
26-06-24 $96.38 +6.84% 1,042,301
26-06-23 $90.21 +0.31% 659,112
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
102.52USD
Average target price
160.64USD
Spread / Average Target
+56.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock